Literature DB >> 8163479

Occupancy of anion binding exosite 2 on thrombin determines Ca2+ dependence of protein C activation.

L W Liu1, A R Rezaie, C W Carson, N L Esmon, C T Esmon.   

Abstract

Thrombomodulin (TM) binds thrombin to form a complex that activates the plasma anticoagulant zymogen protein C. TM is an integral membrane glycoprotein that contains a chondroitin sulfate moiety. Interaction with thrombin involves both the protein component of TM, specifically the growth factor-like repeats 4-6 (TM 4-6), and chondroitin sulfate. Removal of chondroitin sulfate decreases the affinity for thrombin approximately 10-fold and shifts the Ca2+ dependence of protein C activation from simple saturation at > or = 500 microM Ca2+ to a distinct optimum at approximately 100 microM Ca2+. Thrombin possesses two regions of high positive charge, anion binding exosites 1 and 2. Anion binding exosite 1 interacts with the growth factor region of TM while exosite 2 is involved in binding prothrombin activation fragment 2 or heparin. We demonstrate that recombinant TM, truncated at the membrane-spanning domain, or TM 4-6 can bind thrombin when fragment 2 is present either covalently attached (meizothrombin des-fragment 1) or in reversible association. With meizothrombin des-fragment 1, the Ca2+ dependence of protein C activation is independent of the presence of the chondroitin sulfate on TM. At 0.27 mM Ca2+, TM containing chondroitin sulfate binds thrombin (Kd(app) = 0.3 nM) approximately 45 times tighter than meizothrombin des-fragment 1 (Kd(app) = 14 nM). However, the chondroitin-free form binds thrombin (Kd(app) = 2.4 nM) only approximately 4 times tighter than meizothrombin des-fragment 1 (Kd(app) = 9.4 nM). These studies suggest that occupancy of anion binding exosite 2 by either chondroitin sulfate or fragment 2 alters thrombin conformation resulting in the altered Ca2+ dependence of protein C activation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163479

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  The thrombin E192Q-BPTI complex reveals gross structural rearrangements: implications for the interaction with antithrombin and thrombomodulin.

Authors:  A van de Locht; W Bode; R Huber; B F Le Bonniec; S R Stone; C T Esmon; M T Stubbs
Journal:  EMBO J       Date:  1997-06-02       Impact factor: 11.598

2.  cDNA cloning and characterization of a plant protein that may be associated with the harpinPSS-mediated hypersensitive response.

Authors:  C H Chen; H J Lin; M J Ger; D Chow; T Y Feng
Journal:  Plant Mol Biol       Date:  2000-07       Impact factor: 4.076

3.  On scaffold hopping: challenges in the discovery of sulfated small molecules as mimetics of glycosaminoglycans.

Authors:  Preetpal S Sidhu; Philip D Mosier; Qibing Zhou; Umesh R Desai
Journal:  Bioorg Med Chem Lett       Date:  2012-10-24       Impact factor: 2.823

4.  Heparin enhances the catalytic activity of des-ETW-thrombin.

Authors:  C A Goodwin; J J Deadman; B F Le Bonniec; S Elgendy; V V Kakkar; M F Scully
Journal:  Biochem J       Date:  1996-04-01       Impact factor: 3.857

5.  Solulin increases clot stability in whole blood from humans and dogs with hemophilia.

Authors:  Jonathan H Foley; Karl-Uwe Petersen; Catherine J Rea; Lori Harpell; Sandra Powell; David Lillicrap; Michael E Nesheim; Benny Sørensen
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

6.  Inhibition of thrombin activity by prothrombin activation fragment 1.2.

Authors:  Swapan Kumar Dasgupta; Perumal Thiagarajan
Journal:  J Thromb Thrombolysis       Date:  2007-03-02       Impact factor: 2.300

7.  Polyphosphate binds with high affinity to exosite II of thrombin.

Authors:  N J Mutch; T Myles; L L K Leung; J H Morrissey
Journal:  J Thromb Haemost       Date:  2009-12-11       Impact factor: 5.824

Review 8.  Thrombin inhibitors from different animals.

Authors:  A M Tanaka-Azevedo; K Morais-Zani; R J S Torquato; A S Tanaka
Journal:  J Biomed Biotechnol       Date:  2010-10-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.